Abstract
AbstractBoth, recessive (LGMD R1) and dominant (LGMD D4) inheritance occur in calpain 3-related muscular dystrophy. We report a family with calpain-related muscular dystrophy caused by two known variants in the calpain 3 gene (CAPN3, NM_000070.3; (I) c.700G>A, p.Gly234Arg and (II) c.1746-20C>G, p.?). Three family members are compound heterozygous and exhibit a relatively homogeneous phenotype characterized by progressive proximal weakness starting in the third to fourth decade of life in the shoulder girdle and spreading to the legs. Two family members affected only by the p.Gly234Arg heterozygous missense variants show a different phenotype characterized by severe exertional myalgia without overt pareses. We conclude that in our family, the missense variant causes a severe myalgic phenotype without pareses that is aggravated by the second intronic variant and put these findings in the context of previous studies of the same variants.
Funder
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Genetics (clinical),Genetics
Reference20 articles.
1. Straub V, Murphy A, Udd B, group Lws (2018) 229th ENMC international workshop: limb girdle muscular dystrophies - nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscul Disord 28(8):702-710. https://doi.org/10.1016/j.nmd.2018.05.007
2. Angelini C (1993) Calpainopathy. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al, editors, GeneReviews(®). Seattle (WA): University of Washington, Seattle. Copyright © -2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved 1993
3. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N et al (1995) Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81(1):27–40. https://doi.org/10.1016/0092-8674(95)90368-2
4. Angelini C, Nardetto L, Borsato C, Padoan R, Fanin M, Nascimbeni AC et al (2010) The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurol Res 32(1):41–46. https://doi.org/10.1179/174313209X380847
5. Richard I, Hogrel JY, Stockholm D, Payan CA, Fougerousse F, Calpainopathy Study G et al (2016) Natural history of LGMD2A for delineating outcome measures in clinical trials. Ann Clin Transl Neurol 3(4):248–265. https://doi.org/10.1002/acn3.287